Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Prior treatment

• Symptomatic central nervous system (CNS) metastasis, and/or those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
• Most recent systemic anti-cancer treatment or investigational products/devices less than 3 weeks
• Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate
• Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment

Other illness

• Participants with another known malignancy that has required treatment within the last 2 years
• Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions

Other

• Participants with leptomeningeal metastasis
• Pregnant or nursing (lactating) women

• Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \> 3 months
• Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and/or metastatic sarcoma or a selected solid tumor
• Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample
• Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting
• Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic/relapsed refractory setting
• Participants must have at least one measurable target lesion as defined by RECIST v1.1
• Adequate organ and marrow function as listed per protocol
• Must be negative for HIV, HBV, and HCV